WSTNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
WEST PHARMACEUTICAL SERVICES INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 23, 2026
$383.91−0.11 (-0.03%)
Close on Oct 19, 2026
- Market cap
- $27.37B
- P/E (TTM)
- 49.2
- Dividend yield
- 0.22%
West Pharmaceutical Services statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | West Pharmaceutical Services | Industry median |
|---|---|---|
| Market Cap | $27.02B | $230.55M |
| Enterprise Value | $26.79B | $202.97M |
| PE Ratio | 49.16 | 33.40 |
| PS Ratio | 8.12 | 3.11 |
| PB Ratio | 9.04 | 3.14 |
| P/TBV Ratio | 9.40 | 4.57 |
| P/FCF Ratio | 61.84 | 27.25 |
| P/OCF Ratio | 40.80 | 22.35 |
Enterprise value
| Measure | West Pharmaceutical Services | Industry median |
|---|---|---|
| EV / Sales | 8.05 | 2.92 |
| EV / EBITDA | 31.08 | 19.86 |
| EV / EBIT | 39.37 | 24.88 |
| EV / FCF | 61.31 | 27.85 |
Income (trailing twelve months)
| Measure | West Pharmaceutical Services | Industry median |
|---|---|---|
| Revenue | $3.33B | $102.39M |
| Gross Profit | $1.22B | $60.36M |
| Operating Income | $680.40M | -$4.31M |
| Pretax Income | $693.60M | -$2.26M |
| Net Income | $564.90M | -$6.57M |
| EBITDA | $861.80M | -$1.98M |
| EPS (Diluted) | $7.81 | -$0.07 |
Margins
| Measure | West Pharmaceutical Services | Industry median |
|---|---|---|
| Gross Margin | 36.8% | 55.1% |
| Operating Margin | 20.5% | -6.04% |
| Pretax Margin | 20.8% | -4.11% |
| Profit Margin | 17.0% | -10.5% |
| EBITDA Margin | 25.9% | -2.67% |
| FCF Margin | 13.1% | -0.30% |
Returns
| Measure | West Pharmaceutical Services | Industry median |
|---|---|---|
| Return on Equity (ROE) | 19.1% | -19.2% |
| Return on Assets (ROA) | 14.1% | -13.3% |
| Return on Invested Capital (ROIC) | 20.0% | -4.11% |
| Return on Capital Employed (ROCE) | 19.8% | -9.07% |
Growth
| Measure | West Pharmaceutical Services | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 12.4% | 8.85% |
| Net Income Growth (YoY) | 15.8% | 10.6% |
| EPS Growth (YoY) | 17.1% | 10.6% |
| FCF Growth (YoY) | 27.0% | 10.6% |
| Revenue Growth (3Y CAGR) | 2.12% | 7.08% |
| Revenue Growth (5Y CAGR) | 7.44% | 11.8% |
| EPS Growth (3Y CAGR) | -4.23% | 3.06% |
| EPS Growth (5Y CAGR) | 8.24% | 7.64% |
Balance sheet
| Measure | West Pharmaceutical Services | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $435.80M | $37.33M |
| Total Debt | $202.90M | $72.66M |
| Net Cash (Debt) | $232.90M | $3.92M |
| Net Cash Per Share | $3.31 | $0.28 |
| Equity (Book Value) | $2.99B | $57.36M |
| Book Value Per Share | $42.49 | $2.81 |
| Tangible Book Value | $2.88B | $10.71M |
| Working Capital | $1.17B | $54.64M |
Financial position
| Measure | West Pharmaceutical Services | Industry median |
|---|---|---|
| Current Ratio | 2.82 | 2.50 |
| Quick Ratio | 1.79 | 1.54 |
| Debt / Equity | 0.07 | 0.38 |
| Debt / EBITDA | 0.24 | 2.31 |
| Debt / FCF | 0.46 | 3.50 |
| Net Debt / EBITDA | -0.27 | 1.53 |
| Interest Coverage | 151.20 | -1.81 |
Cash flow (trailing twelve months)
| Measure | West Pharmaceutical Services | Industry median |
|---|---|---|
| Operating Cash Flow | $662.20M | -$653.46K |
| Capital Expenditures | -$225.30M | -$3.69M |
| Free Cash Flow | $436.90M | -$835.02K |
| FCF Per Share | $6.21 | -$0.02 |
Efficiency
| Measure | West Pharmaceutical Services | Industry median |
|---|---|---|
| Asset Turnover | 0.83 | 0.59 |
| Inventory Turnover | 4.84 | 2.21 |
| Revenue Per Employee | $308.04K | $322.57K |
| Profits Per Employee | $52.31K | -$51.88K |
| Employee Count | 10,800 | 185 |
Dividends and yields
| Measure | West Pharmaceutical Services | Industry median |
|---|---|---|
| Earnings Yield | 2.09% | -6.91% |
| FCF Yield | 1.62% | -0.56% |
| Dividend Yield | 0.22% | 0.81% |
| Buyback Yield | 1.68% | 0.78% |
| Shareholder Yield | 1.91% | 0.80% |
| Dividend Per Share | $0.86 | $0.72 |
| Dividend Growth (YoY) | 4.88% | 4.80% |
| Years of Dividend Growth | 11 | 0 |
| Payout Ratio | 11.0% | 30.3% |
| FCF Payout Ratio | 14.3% | 21.9% |
Shares
| Measure | West Pharmaceutical Services | Industry median |
|---|---|---|
| Shares Outstanding | 70,375,800 | 44,856,700 |
| Shares Change (YoY) | -1.13% | 3.35% |
| Shares Change (QoQ) | -0.71% | 0.27% |
| Float | 69,910,000 | 37,097,900 |
| Shares Held by Insiders | 0.66% | 10.6% |
| Shares Held by Institutions | 100.2% | 63.5% |
Taxes
| Measure | West Pharmaceutical Services | Industry median |
|---|---|---|
| Income Tax | $144.20M | $1.52M |
| Effective Tax Rate | 20.8% | 18.6% |
Scores
| Measure | West Pharmaceutical Services | Industry median |
|---|---|---|
| Graham Number | $86.41 | $34.37 |
| Graham Upside | -77.5% | -57.7% |
| Altman Z-Score | 18.22 | 1.95 |
| Piotroski F-Score | 8 | 5 |
| Beneish M-Score | -2.79 | -2.64 |
Calculated by StockData from West Pharmaceutical Services's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.